Persistent Expression of 3-methylcholanthrene-inducible Cytochromes P4501A in Rat Hepatic and Extrahepatic Tissues
Overview
Authors
Affiliations
We reported earlier that 3-methylcholanthrene (MC) persistently induces hepatic ethoxyresorufin O-deethylase activities (CYP1A1) in rats for up to 45 days. In this investigation, we tested the hypotheses that persistent expression of CYP1A1 activities is paralleled by sustained induction of CYP1A1/CYP1A2 apoproteins and their mRNAs and that this phenomenon is mediated by mechanisms other than retention of MC in the rat. Rats were given MC (93 micromol/kg) i.p., once daily for 4 days, and CYP1A1/1A2 parameters were measured in liver at selected time points. MC-elicited increases in CYP1A1/1A2 activities, apoprotein contents, and mRNA levels were sustained for several weeks after the last dose of MC treatment. MC also caused long-term induction of CYP1A1 in lungs and mammary glands. Rats treated with [(3)H]MC once daily for 4 days excreted 92. 3% of the administered radioactivity in feces and urine by day 15. The intrahepatic concentration of MC at the 15-day time point was 270 pmol/g. Dose-response studies showed that administration of MC (2 micromol/kg), which produced an intrahepatic concentration of 271 pmol/g after 24 h, did not induce CYP1A1/1A2 activities, strongly suggesting that the sustained induction of CYP1A1/1A2 was not due to retention of the parent MC in the body. Electrophoretic mobility shift assays revealed that persistent CYP1A1 induction by MC involved Ah receptor-independent mechanisms. In conclusion, our results support the hypothesis that persistent expression of CYP1A1/1A2 by MC is mediated by mechanisms independent of the retention of the parent carcinogen.
Stading R, Gastelum G, Chu C, Jiang W, Moorthy B Semin Cancer Biol. 2021; 76:3-16.
PMID: 34242741 PMC: 8728691. DOI: 10.1016/j.semcancer.2021.07.001.
Gastelum G, Jiang W, Wang L, Zhou G, Borkar R, Putluri N Toxicol Sci. 2020; 177(2):347-361.
PMID: 32726451 PMC: 7818899. DOI: 10.1093/toxsci/kfaa107.
Polycyclic aromatic hydrocarbons: from metabolism to lung cancer.
Moorthy B, Chu C, Carlin D Toxicol Sci. 2015; 145(1):5-15.
PMID: 25911656 PMC: 4408964. DOI: 10.1093/toxsci/kfv040.
Polycyclic aromatic hydrocarbons and digestive tract cancers: a perspective.
Diggs D, Huderson A, Harris K, Myers J, Banks L, Rekhadevi P J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2011; 29(4):324-57.
PMID: 22107166 PMC: 3247201. DOI: 10.1080/10590501.2011.629974.
Zhou G, Richardson M, Fazili I, Wang J, Donnelly K, Wang F Toxicol Appl Pharmacol. 2010; 249(3):224-30.
PMID: 20888851 PMC: 3001276. DOI: 10.1016/j.taap.2010.09.019.